비교리스트

 카트 문의
시장보고서
상품코드
1514208

세계의 간암 치료제 시장

Liver Cancer Drugs
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 277 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 간암 치료제 시장은 2030년까지 93억 달러에 달할 전망

2023년에 28억 달러로 평가된 세계의 간암 치료제 시장은 2023년부터 2030년까지 분석 기간에 CAGR 18.4%로 성장할 전망이며, 2030년에는 93억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 표적 약물 치료는 CAGR 18.5%로 성장을 지속하고, 분석 기간 종료 시 51억 달러에 달할 것으로 예측됩니다. 화학요법 분야의 성장률은 분석 기간의 CAGR로 16.2%로 추정됩니다.

미국 시장은 추정 7억 6,380만 달러, 중국은 CAGR 24.4%로 성장 예측

미국의 간암 치료제 시장은 2023년 7억 6,380만 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 분석 기간 2023년부터 2030년까지 CAGR 24.4%로 전망되며, 2030년까지 시장 규모 23억 달러에 이를 것으로 예측됩니다. 다른 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 13.6%와 15.7%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 약 14.5%로 성장할 것으로 예측됩니다.

간암 치료제-주요 동향 및 촉진요인

간암 치료제에는 간세포암(HCC) 및 간의 다른 악성 종양의 치료를 목적으로 한 다양한 치료 옵션이 포함되어 있습니다. 원발성 간암에서 가장 흔한 간세포암은 B형 간염과 C형 간염, 비알코올성 지방간염(NASH), 간경변 등의 만성 간 질환에 따라 발병하는 경우가 많습니다. 간의 기능은 복잡하고 체내의 대사 과정에서 중요한 역할을 담당하고 있기 때문에 간암의 치료는 역사적으로 어려운 과제였습니다. 수술 및 경동맥 화학 색전 요법(TACE)과 같은 국소 요법을 포함한 전통적인 치료법은 전신 치료의 출현으로 보완되었습니다. 소라페닙 및 렘바티닙과 같은 표적 요법은 종양 성장 및 혈관신생에 관여하는 특정 경로를 억제함으로써 진행 간암의 관리에 필수적입니다. 이러한 약물은 생존에 큰 이익을 제공하지만, 환자의 QOL에 영향을 미치는 부작용을 수반하는 경우가 많습니다.

최근 면역요법이 간암 치료의 획기적인 접근법으로 부상해 왔습니다. 펨브롤리주맙이나 니볼루맙 등의 면역 체크포인트 억제제는 암세포에 대한 신체의 면역반응을 증강하는 것으로 유망시되고 있습니다. 이러한 치료제는 면역계의 활동을 저해하는 단백질을 차단함으로써 T세포가 암세포를 보다 효과적으로 공격할 수 있도록 합니다. 또한, 면역요법을 표적치료 및 기타 치료법과 통합하는 병용요법도 임상시험에서 적극적으로 검토되고 있습니다. 예를 들어, 아테졸리주맙과 베바시주맙의 병용 요법은 전통적인 단일 요법에 비해 치료 성적 개선을 보여줍니다. 이러한 진보는 보다 개별화된 효과적인 치료요법으로의 시프트를 강조하는 것이며, 생존기간의 연장뿐만 아니라 간암 환자의 전체적인 QOL의 향상을 목표로 하는 것입니다.

간암 치료제 시장의 성장은 여러 요인에 의해 초래됩니다. 첫째, 특히 간염 감염이나 NASH의 유병률이 높은 지역에서 간암의 이환율이 상승하여 효과적인 치료에 대한 수요가 높아지고 있습니다. 둘째, 의약품 개발과 유전체 연구의 기술적 진보는 신규 치료 표적의 발견과 보다 효과적인 약물의 개발을 촉진하고 있습니다. 셋째, 면역요법 및 표적치료의 성공이 연구개발에 많은 투자를 불러들여 경쟁적이고 혁신적인 시장환경이 조성되고 있습니다. 또한 규제 당국이 획기적인 치료제에 대한 신속한 승인을 받고 있기 때문에 환자에게 새로운 치료법을 제공하는 것이 가속화되고 있습니다. 시너지 효과와 치료 성적 개선을 가져오는 병용 요법의 채용이 증가하고 있는 것도 시장 성장을 더욱 뒷받침하고 있습니다. 또한 조기 진단 및 고급 치료 옵션의 이점에 대한 건강 관리 제공업체와 환자의 의식이 높아짐에 따라 신약 채용률이 높아지고 있습니다. 마지막으로, 신흥국의 건강 관리 인프라 확충과 선진 의료에 대한 액세스가 시장 성장의 새로운 기회를 낳고, 혁신적인 간암 치료가 보다 많은 환자에게 전달될 수 있도록 하고 있습니다. 이러한 요인이 종합적으로 간암 치료제 시장의 견조한 확대와 역동적인 진화에 기여하고 있습니다.

조사 대상 기업 예(총 52건)

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Merck & Co., Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향 및 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

AJY 24.07.24

Global Liver Cancer Drugs Market to Reach US$9.3 Billion by 2030

The global market for Liver Cancer Drugs estimated at US$2.8 Billion in the year 2023, is expected to reach US$9.3 Billion by 2030, growing at a CAGR of 18.4% over the analysis period 2023-2030. Targeted Drug Therapy, one of the segments analyzed in the report, is expected to record a 18.5% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 16.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$763.8 Million While China is Forecast to Grow at 24.4% CAGR

The Liver Cancer Drugs market in the U.S. is estimated at US$763.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 24.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.6% and 15.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.5% CAGR.

Liver Cancer Drugs - Key Trends and Drivers

Liver cancer drugs encompass a diverse range of therapeutic options aimed at treating hepatocellular carcinoma (HCC) and other malignancies of the liver. HCC, the most common type of primary liver cancer, often develops in the context of chronic liver diseases such as hepatitis B and C infections, non-alcoholic steatohepatitis (NASH), and cirrhosis. The treatment landscape for liver cancer has historically been challenging due to the complexity of the liver’s function and its vital role in the body’s metabolic processes. Traditional approaches, including surgery and localized therapies like transarterial chemoembolization (TACE), have been complemented by the advent of systemic treatments. Targeted therapies, such as sorafenib and lenvatinib, have been integral in managing advanced liver cancer by inhibiting specific pathways involved in tumor growth and angiogenesis. These drugs have provided significant survival benefits, although they are often associated with considerable side effects that can impact patients' quality of life.

In recent years, immunotherapy has emerged as a groundbreaking approach in the treatment of liver cancer. Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, have shown promise in enhancing the body’s immune response against cancer cells. These therapies work by blocking proteins that inhibit immune system activity, thus allowing T-cells to attack cancer cells more effectively. Additionally, combination therapies that integrate immunotherapies with targeted treatments or other modalities are being actively explored in clinical trials. The combination of atezolizumab and bevacizumab, for example, has demonstrated improved outcomes compared to traditional monotherapies. These advancements underscore a shift towards more personalized and effective treatment regimens, which not only aim to extend survival but also improve the overall quality of life for patients with liver cancer.

The growth in the liver cancer drugs market is driven by several factors. Firstly, the rising incidence of liver cancer, particularly in regions with high prevalence of hepatitis infections and NASH, has increased the demand for effective treatments. Secondly, technological advancements in drug development and genomic research have facilitated the discovery of novel therapeutic targets and the development of more effective drugs. Thirdly, the success of immunotherapies and targeted therapies has attracted significant investment in research and development, fostering a competitive and innovative market environment. Additionally regulatory agencies are providing accelerated approvals for breakthrough therapies, which helps expedite the availability of new treatments to patients. The increasing adoption of combination therapies, which offer synergistic effects and improved outcomes, further drives market growth. Furthermore, heightened awareness among healthcare providers and patients about the benefits of early diagnosis and advanced treatment options has led to a higher adoption rate of new drugs. Lastly, the expansion of healthcare infrastructure and access to advanced medical treatments in emerging economies is creating new opportunities for market growth, ensuring that innovative liver cancer therapies reach a broader patient population. These factors collectively contribute to the robust expansion and dynamic evolution of the liver cancer drugs market.

Select Competitors (Total 52 Featured) -

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Merck & Co., Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Liver Cancer Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Liver Cancer Expands Addressable Market Opportunity
    • Advances in Immunotherapy Throws the Spotlight on Novel Treatment Approaches
    • Rising Geriatric Population Strengthens Business Case for Liver Cancer Drugs
    • Enhanced Drug Delivery Systems Drives Adoption of Liver Cancer Drugs
    • Increasing Awareness and Early Diagnosis Spurs Growth in Treatment Demand
    • Technological Innovations in Drug Development Generates New Market Opportunities
    • Robust Pipeline of Liver Cancer Drugs Boost Future Market Growth
    • Rising Healthcare Expenditure Sustains Growth of Liver Cancer Treatment Market
    • Combination Therapies Expand Treatment Options and Market Potential
    • Personalized Treatment Plans Enhance Treatment Efficacy and Market Demand
    • Improved Patient Outcomes Generates Confidence in Liver Cancer Drug Market
    • Increasing Use of Biomarkers and Genomics Expands Addressable Market Opportunity
    • Market Penetration in Emerging Economies Fuel Growth Potential
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Liver Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Liver Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Liver Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Liver Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Targeted Drug Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Targeted Drug Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Targeted Drug Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • JAPAN
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • CHINA
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • EUROPE
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Liver Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Liver Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • FRANCE
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • GERMANY
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Liver Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Liver Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • INDIA
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Liver Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Liver Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Liver Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Liver Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Liver Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Liver Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
  • AFRICA
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제